Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
Incannex Healthcare to incorporate virtual reality in a new R&D partnership aimed at psychedelics-based therapies.
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
The Biden Strategy On Mental Health: Lots Of Bandaids, No Substance
With a mental health catastrophe in the United States spiraling out of control, the Biden "plan" is just more of what has failed.
Apex Labs granted phase 2a Clinical Trial Application approval by Health Canada for treatment of PTSD in Veterans
Apex has secured its Veteran patient base, clinical trial location and Qualified Investigator for its phase 2a program expected to launch as early as Q2/Q3 2022.
Nickel price jumps 30% to 15-year high
Nickel prices jumped 30% to near 15-year highs and aluminum climbed to a record above $4 000/t as fears of major disruptions to supplies due to financial sanctions on Russia fuelled a buying frenzy.
Gold hits 1.5-year high
Gold prices are higher in midday U.S. trading Monday, but well down from their overnight 1.5-year high of $2,007.50.
Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.
GOP Missouri Lawmaker Files Psychedelics Therapy And Decriminalization Bill
A Missouri Republican lawmaker filed a bill on Tuesday that would legalize a wide range of psychedelics for therapeutic use at designated care facilities while further decriminalizing low-level possession in general.
Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care
Field Trip Health announces a strategic partnership with Cerebral, "the fastest growing online mental health platform".
MindMed Announces Publication of Study Comparing the Acute Effects of LSD and Psilocybin in Healthy Subjects
MindMed announced the peer-reviewed publication of a study directly comparing the acute effects of LSD and psilocybin in healthy subjects.
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects
MindMed releases a peer-reviewed study that confirms the similar psychoactive effects of psilocybin and Lysergic Acid Diethylamide (LSD).
